Inflammation, oxidative stress, glomerular filtration rate, and albuminuria in elderly men: A cross-sectional study

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Nerpin, Elisabet ^a,f   Helmersson Karlqvist, Johanna ^b,c   Risérus, Ulf ^a   Sundström, Johan ^b   Larsson, Anders ^c   Jobs, Elisabeth ^a,f   Basu, Samar ^b,e   Ingelsson, Erik ^d   Ärnlöv, Johan ^a,f  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f DALARNA UNIVERSITY   (Sweden)

Author keywords

Glomerular filtration rate and albuminuria; Inflammation; Oxidative stress

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; CYTOKINE; PROSTAGLANDIN SYNTHASE;

AGED; ALBUMINURIA; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; CROSS-SECTIONAL STUDY; GLOMERULUS FILTRATION RATE; HUMAN; INFLAMMATION; KIDNEY; LONGITUDINAL STUDY; MALE; METABOLISM; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RISK FACTOR; STATISTICAL MODEL; SWEDEN; URINE;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; CYTOKINES; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MULTIVARIATE ANALYSIS; OXIDATIVE STRESS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SWEDEN;

EID: 84871543971     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-537     Document Type: Article

References (39)

1. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ, J Am Soc Nephrol 2005 16 489 495 10.1681/ASN.2004030203 15590763 (Pubitemid 41725146)
2. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S, Ann Intern Med 2001 134 629 636 11304102 (Pubitemid 32322240)
3. Epidemiology of cardiovascular risk factors in chronic renal disease. Coresh J, Longenecker JC, Miller ER 3rd, Young HJ, Klag MJ, J Am Soc Nephrol 1998 9 24 S30 11443765
4. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. Muntner P, He J, Astor BC, Folsom AR, Coresh J, J Am Soc Nephrol 2005 16 529 538 10.1681/ASN.2004080656 15625072 (Pubitemid 41725151)
5. Risks associated with renal dysfunction in patients in the coronary care unit. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S, J Am Coll Cardiol 2000 36 679 684 10.1016/S0735-1097(00)00774-9 10987584
6. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J, Clin Nephrol 2002 58 190 197 12356187 (Pubitemid 34994045)
7. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM, Kidney Int 2002 62 1524 1538 10.1046/j.1523-1755.2002.00600.x 12371953 (Pubitemid 35286260)
8. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, Cummings SR, Harris TB, Shlipak MG, Kidney Int 2007 71 239 244 10.1038/sj.ki.5002042 17183246 (Pubitemid 46160924)
9. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J, Kidney Int 2004 65 1009 1016 10.1111/j.1523-1755.2004.00465.x 14871421 (Pubitemid 38251077)
10. Oxidative stress is progressively enhanced with advancing stages of CKD. Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D, Am J Kidney Dis 2006 48 752 760 10.1053/j.ajkd.2006. 08.015 17059994 (Pubitemid 44740054)
11. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, Bleyer A, Newman A, Siscovick D, Psaty B, JAMA 2005 293 1737 1745 10.1001/jama.293.14.1737 15827312
12. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C, Kidney Int 2005 67 2330 2337 10.1111/j.1523-1755.2005.00338.x 15882276 (Pubitemid 41623394)
13. Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation. Basu S, Med Res Rev 2007 27 435 468 10.1002/med.20098 17191216 (Pubitemid 46991953)
14. F2-isoprostanes in human health and diseases: from molecular mechanisms to clinical implications. Basu S, Antioxid Redox Signal 2008 10 1405 1434 10.1089/ars.2007.1956 18522490
15. Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. Kadiiska MB, Gladen BC, Baird DD, Graham LB, Parker CE, Ames BN, Basu S, Fitzgerald GA, Lawson JA, Marnett LJ, et al. Free Radic Biol Med 2005 38 711 718 10.1016/j.freeradbiomed.2004.10.024 15721981 (Pubitemid 40249741)
16. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Roberts LJ, Morrow JD, Free Radic Biol Med 2000 28 505 513 10.1016/S0891- 5849(99)00264-6 10719231 (Pubitemid 30136031)
17. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Larsson A, Malm J, Grubb A, Hansson LO, Scand J Clin Lab Invest 2004 64 25 30 10.1080/00365510410003723 15025426 (Pubitemid 38283206)
18. Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2alpha: an index for inflammation via cyclooxygenase catalysed lipid peroxidation. Basu S, Prostaglandins Leukot Essent Fatty Acids 1998 58 347 352 10.1016/S0952-3278(98) 90070-9 9690712 (Pubitemid 28329082)
19. Radioimmunoassay of 8-iso-prostaglandin F2alpha: an index for oxidative injury via free radical catalysed lipid peroxidation. Basu S, Prostaglandins Leukot Essent Fatty Acids 1998 58 319 325 10.1016/S0952-3278(98)90042-4 9654406 (Pubitemid 28275903)
20. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Helmersson J, Vessby B, Larsson A, Basu S, Circulation 2004 109 1729 1734 10.1161/01.CIR.0000124718.99562.91 15037525 (Pubitemid 38500674)
21. Not all inflammatory markers are linked to kidney function: results from a population-based study. Pruijm M, Ponte B, Vollenweider P, Mooser V, Paccaud F, Waeber G, Marques-Vidal P, Burnier M, Bochud M, Am J Nephrol 2012 35 288 294 10.1159/000335934 22398717
22. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Stuveling EM, Hillege HL, Bakker SJ, Gans RO, De Jong PE, De Zeeuw D, Kidney Int 2003 63 654 661 10.1046/j.1523-1755.2003.00762.x 12631131 (Pubitemid 36126812)
23. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, Furberg CD, Psaty BM, Circulation 2003 107 87 92 10.1161/01.CIR. 0000042700.48769.59 12515748 (Pubitemid 36070938)
24. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Muntner P, Hamm LL, Kusek JW, Chen J, Whelton PK, He J, Ann Intern Med 2004 140 9 17 14706967
25. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Upadhyay A, Larson MG, Guo CY, Vasan RS, Lipinska I, O'Donnell CJ, Kathiresan S, Meigs JB, Keaney JF Jr, Rong J, et al. Nephrol Dial Transplant 2011 26 920 926 10.1093/ndt/gfq471 20682604
26. Association of kidney function with inflammatory and procoagulant markers in a diverse cohort: a cross-sectional analysis from the Multi-Ethnic Study of Atherosclerosis (MESA). Keller C, Katz R, Cushman M, Fried LF, Shlipak M, BMC Nephrol 2008 9 9 10.1186/1471-2369-9-9 18681974
27. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Kshirsagar AV, Bomback AS, Bang H, Gerber LM, Vupputuri S, Shoham DA, Mazumdar M, Ballantyne CM, Paparello JJ, Klemmer PJ, Am J Cardiol 2008 101 401 406 10.1016/j.amjcard.2007. 08.041 18237609 (Pubitemid 351175628)
28. C-reactive protein and microalbuminuria in a multi-ethnic Asian population. Sabanayagam C, Lee J, Shankar A, Lim SC, Wong TY, Tai ES, Nephrol Dial Transplant 2010 25 1167 1172 10.1093/ndt/gfp591 19914996
29. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Cottone S, Mule G, Guarneri M, Palermo A, Lorito MC, Riccobene R, Arsena R, Vaccaro F, Vadala A, Nardi E, et al. Nephrol Dial Transplant 2009 24 497 503 18772174
30. Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. Chade AR, Best PJ, Rodriguez-Porcel M, Herrmann J, Zhu X, Sawamura T, Napoli C, Lerman A, Lerman LO, Kidney Int 2003 64 962 969 10.1046/j.1523-1755.2003.00170.x 12911546 (Pubitemid 37013832)
31. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, Muller D, Park JK, Luft FC, Mervaala EM, Hypertension 2001 37 433 439 10.1161/01.HYP.37.2.433 11230314 (Pubitemid 32199007)
32. Implications for kidney disease in obese children and adolescents. Savino A, Pelliccia P, Giannini C, de Giorgis T, Cataldo I, Chiarelli F, Mohn A, Pediatr Nephrol 2011 26 749 758 10.1007/s00467-010-1659-y 21308381
33. Using isoprostanes as biomarkers of oxidative stress: some rarely considered issues. Halliwell B, Lee CY, Antioxid Redox Signal 2010 13 145 156 10.1089/ars.2009.2934 20001743
34. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB, Kidney Int 2001 59 1960 1966 10.1046/j.1523-1755.2001.0590051960.x 11318969 (Pubitemid 32336813)
35. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Basu S, Sjoquist B, Stjernschantz J, Resul B, Prostaglandins Leukot Essent Fatty Acids 1994 50 161 168 10.1016/0952-3278(94) 90139-2 8022849 (Pubitemid 24110315)
36. Metabolism of 8-iso-prostaglandin F2alpha. Basu S, FEBS Lett 1998 428 32 36 10.1016/S0014-5793(98)00481-5 9645469 (Pubitemid 28266822)
37. First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Grubb A, Blirup-Jensen S, Lindstrom V, Schmidt C, Althaus H, Zegers I, Clin Chem Lab Med 2010 48 1619 1621 21034257
38. Standardization of Cystatin C: development of primary and secondary reference preparations. Blirup-Jensen S, Grubb A, Lindstrom V, Schmidt C, Althaus H, Scand J Clin Lab Invest 2008 241 67 70 (Pubitemid 351883660)
39. Estimating glomerular filtration rate from serum creatinine and cystatin C. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, et al. N Engl J Med 2012 367 20 29 10.1056/NEJMoa1114248 22762315